Výsledky vyhledávání - Mark D. Pegram

Upřesnit hledání
  1. 1
    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer Autor Mark D. Pegram, Christian Jackisch, Stephen Johnston

    Vydáno 2023
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Triple negative breast cancer: unmet medical needs

    Triple negative breast cancer: unmet medical needs Autor Sumanta K. Pal, Barrett H. Childs, Mark D. Pegram

    Vydáno 2010
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Autor Richard J. Pietras, Mark D. Pegram, Richard S. Finn, Daniel A Maneval, Dennis J. Slamon

    Vydáno 1998
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Autor Mark D. Pegram, Richard Finn, Karo K. Arzoo, Malgorzata Beryt, Richard J. Pietras, Dennis J. Slamon

    Vydáno 1997
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting

    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting Autor Todd A. Duncombe, Chi‐Chih Kang, Santanu Maity, Toby M. Ward, Mark D. Pegram, Niren Murthy, Amy E. Herr

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity Autor Alexis V. Forterre, Jing‐Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey, A. Matin

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Role of Fcγ receptors in HER2-targeted breast cancer therapy

    Role of Fcγ receptors in HER2-targeted breast cancer therapy Autor Antonino Musolino, William J. Gradishar, Hope S. Rugo, Jeffrey L. Nordstrom, Edwin P. Rock, Fernanda I. Arnaldez, Mark D. Pegram

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 Autor Nadine Norton, Rebecca M. Olson, Mark D. Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer Autor Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy

    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy Autor Claire E. Gustafson, Rohit R. Jadhav, Wenqiang Cao, Qian Qi, Mark D. Pegram, Lü Tian, Cornelia M. Weyand, Jörg J. Goronzy

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Autor Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review

    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review Autor Hope S. Rugo, Giuseppe Curigliano, Fátima Cardoso, WJ Gradishar, Mark D. Pegram, C.H.H. Barrios, J. Cortés Castán, Eduardo J. Pennella, Rafael Muniz

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–pos... Autor Xavier Pivot, Mark D. Pegram, Javier Cortés, Diana Lüftner, Gary H. Lyman, Giuseppe Curigliano, Igor Bondarenko, Ye Chan Yoon, Younsoo Kim, Chul Kim

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Autor Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, Julie Maltzman, John Forster, S. D. Rubin, Steven H. Stein, Harold J. Burstein

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation Autor Jing‐Hung Wang, Alexis V. Forterre, Jinjing Zhao, Daniel O. Frimannsson, Alain Delcayre, Travis J. Antes, Bradley Efron, Stefanie S. Jeffrey, Mark D. Pegram, A. Matin

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer Autor José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall... Autor Véronique Dièras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim T. Blackwell, Silke Hoersch, Jin Xu, Marjorie Green, Luca Gianni

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Autor Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton

    Vydáno 2001
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer Autor Marzia Locatelli, Philippe Aftimos, Elizabeth Claire Dees, Patricia LoRusso, Mark D. Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M. Naveed Shaik, Kenneth A. Kern, Giuseppe Curigliano

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer Autor Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: